Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: A Novel Therapy in the Treatment of Cholesterol Crystal Embolism-Induced Kidney Injury. [PDF]
Kidney MedStrimaitis BJ, Francis L, O'Sullivan ED.
europepmc +1 more source
<i>Proprotein Convertase Subtilisin</i>/<i>Kexin Type 9</i> (<i>PCSK9</i>) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia. [PDF]
Int J Mol SciWoźniak E +6 more
europepmc +1 more source
Apparent Nonresponse to PCSK9 Inhibition in a Patient With Heterozygous Familial Hypercholesterolemia Due to PCSK9 Gene Duplication. [PDF]
JACC Case RepPindwarawala M, Bose S, Brunham LR.
europepmc +1 more source
Corneal Arcus, Xanthomas, and Finger Deformities in a Young Woman With Homozygous Familial Hypercholesterolemia. [PDF]
Case Rep MedBagheri B, Shokri F, Farzaneh AH.
europepmc +1 more source
Coronary artery bypass grafting in a 14-year-old boy with compound heterozygous LDLR familial hypercholesterolemia: a case report. [PDF]
Front PediatrZhu K, Zhang F, Wang J, Li C.
europepmc +1 more source
Do Anti-PCSK9 Monoclonal Antibodies Have Pleiotropic Effects? [PDF]
JACC Basic Transl SciFerri N.
europepmc +1 more source
Effectiveness of combining PCSK9 inhibitors with statins on major adverse cardiovascular events and lipid levels in patients after percutaneous coronary intervention: a systematic review and meta-analysis. [PDF]
Front Cardiovasc MedCao Z +5 more
europepmc +1 more source
Related searches: